Exploring Selective Testing and Future Uses of Aldose Reductase Inhibitors in Cardiomyopathy Patients

Heart failure is an increasingly recognized complication in chronic diabetes that may be caused by a number of processes including direct effects of hyperglycemia on the heart muscle. So-called diabetic cardiomyopathy may affect up to 20% of people with chronic diabetes and represents a unique target for treatment. 

 In this interview, James Januzzi, MD, FACC, and Alison L. Bailey, MD FACC discuss the primary results from the ARISE-HF study: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL